+

WO1998006398A1 - Antagonistes du recepteur il-8 - Google Patents

Antagonistes du recepteur il-8 Download PDF

Info

Publication number
WO1998006398A1
WO1998006398A1 PCT/US1997/014582 US9714582W WO9806398A1 WO 1998006398 A1 WO1998006398 A1 WO 1998006398A1 US 9714582 W US9714582 W US 9714582W WO 9806398 A1 WO9806398 A1 WO 9806398A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
alkyl
4alkyl
heterocyclic
heteroaryl
Prior art date
Application number
PCT/US1997/014582
Other languages
English (en)
Inventor
Deborah Lynn Bryan
John Gerald Gleason
Katherine L. Widdowson
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP10510107A priority Critical patent/JP2000516620A/ja
Priority to EP97938426A priority patent/EP0939634A4/fr
Publication of WO1998006398A1 publication Critical patent/WO1998006398A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Definitions

  • This invention relates to novel guanidine substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 mediated diseases.
  • Interleukin-8 Interleukin-8
  • NAP-1 neutrophil attractant/activation protein- 1
  • MDNCF monocyte derived neutrophi! chemotactic factor
  • NAF neutrophil activating factor
  • T-cell lymphocyte chemotactic factor T-cell lymphocyte chemotactic factor.
  • Interleukin-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells. It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-l ⁇ , IL-l ⁇ or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP. M.
  • Gro ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 also belong to the chemokine ⁇ family. Like IL-8 these chemokines have also been referred to by different names. For instance GRO ⁇ , ⁇ , ⁇ have been referred to as MGSA ⁇ , ⁇ and ⁇ respectively
  • IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 stimulate a number of functions in vitro. They have all been shown to have chemoattractant properties for neutrophils, while IL-8 and GRO ⁇ have demonstrated T-lymphocytes, and basophiles chemotactic activity.
  • IL-8 can induce histamine release from basophils from both normal and atopic individuals GRO- ⁇ and IL-8 can in addition, induce Jysozomal enzyme release and respiratory burst from neutrophils.
  • IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis. This may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many known diseases are characterized by massive neutrophil infiltration.
  • GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 promote the accumulation and activation of neutrophils
  • these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis, Baggiolini et al, FEBS Lett. 307. 97 ( 1992); Miller et al. Crit. Rev. Immunol. 12. 17 ( 1992); Oppenheim et al. Annu. Rev. Immunol. 9. 617 (1991): Seitz et al., J. Clin. Invest. 87. 463 (1991 ): Miller et al.. Am. Rev. Respir. Pis. 146.
  • ELR chemokines (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis. Strieter et al, Science 258, 1798 (1992).
  • IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the B-receptor.
  • the development of non-peptide small molecule antagonists for members of this receptor family has precedent. For a review see R. Freidinger in: Progress in Drug Research. Vol. 40, pp.
  • IL-8R ⁇ which binds only IL-8 with high affinity
  • IL-8R ⁇ which has high affinity for IL-8 as well as for GRO- ⁇ , GRO ⁇ , GRO ⁇ and NAP-2.
  • IL-8R ⁇ Two high affinity human IL-8 receptors (77% homology) have been characterized: IL-8R ⁇ , which binds only IL-8 with high affinity, and IL-8R ⁇ , which has high affinity for IL-8 as well as for GRO- ⁇ , GRO ⁇ , GRO ⁇ and NAP-2.
  • This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 ⁇ or ⁇ receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the chemokine is IL-8.
  • This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • Z is cyano, ORj h C(O)NR 15 R 16 , R 18 , C(O)R ⁇ i , or S(O) 2 R ⁇ 7 ;
  • A is nitrogen, provided that only one or two of the A moieties are nitrogen and the remainder are carbon substituted by hydrogen or Rj ;
  • R is any functional moiety having an ionizable hydrogen and a pKa of 10 or less;
  • Rl is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted Ci -io alkyl; Cj-io alkyl; C2-10 alkenyl; Ci-io alkoxy; halosubstituted -io alkoxy; azide; (CRgRg)q S(O) t R4; hydroxy; hydroxy C]_4alkyl; aryl; aryl Cj-4 alkyl; aryloxy; aryl -4 alkyloxy; heteroaryl; heteroarylalkyl; heterocyclic, heterocyclic Cj-4alkyl; heteroaryl Cj-4 alkyloxy; aryl C2- 10 alkenyl; heteroaryl C2- 10 alkenyl; heterocyclic C2-10 alkenyl; (CR 8 R )qNR4R5; C2-10 alkenyl
  • R4 and R5 are independently hydrogen, optionally substituted C 1 - ⁇ % alkyl, optionally substituted aryl, optionally substituted aryl C]-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C ⁇ _4alkyl, heterocyclic, heterocyclic C1.4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S; R6 and R7 are independently hydrogen or a Ci-4 alkyl group; or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur; Y is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted C i- io alkyl; C i- io alkyl; C2-J0 alkenyl; C i- io alkoxy; hal
  • NR4C(O)Ri 1 (CR 8 R 8 )q NHS(O) 2 Rd, (CR 8 R 8 )q S(O)2NR 4 R 5 : or two Y moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring; n is an integer having a value of 1 to 3; m is an integer having a value of 1 to 3;
  • R 8 is independently selected from hydrogen or C1-4 alkyl
  • RlO is C MO alkyl C(O)2R8;
  • R l l is hydrogen, C i-4 alkyl, optionally substituted aryl, optionally substituted aryl
  • Rl2 is hydrogen, Ci- io alkyl, optionally substituted aryl or optionally substituted arylalkyl
  • Rl 3 and R14 are independently hydrogen, optionally substituted C1-4 alkyl, or one of R13 and R14 may be optionally substituted aryl;
  • Rj5 and Rjg are independently hydrogen, optionally substituted C 1 -4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi-4alkyl, optionally substituted heterocyclic, optionally substituted heterocyclicC ] -4alkyl, or R15 and Rj may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur;
  • R 17 is C 1-4 alkyl, NR15R16, ORj 1, optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC i-4alkyl;
  • Rjg is optionally substituted Cj-4 alkyl, optionally substituted aryl, optionally substituted aryl C] -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC i-4alkyl;
  • Rj9 is Ci-4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC j-4alkyl, heterocyclic, or heterocyclicC ⁇ _4alkyl, wherein the all of these moieties may be optionally substituted;
  • R f l is NRgR7, alkyl, arylC ⁇ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, hetroaryl-C ]-4 alkyl, heteroaryIC2_4 alkenyl, heterocyclic, heterocyclicC 1-4 alkyl, wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic, and heterocyclic alkyl rings may be optionally substituted;
  • the E containing ring is optionally selected from
  • the compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokines which bind to the IL-8 ⁇ and ⁇ receptors.
  • Chemokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section.
  • R is suitably any functional moiety which provides an ionizable hydrogen having a pKa of 10 or less, preferably from about 3 to 9, more preferably from about 3 to 7.
  • Such functional groups include, but are not limited to, hydroxy, carboxylic acid, thiol, -SR2,-OR2, -NH-C(O)R a , -C(O)NR6'R7', a substituted sulfonamides of the formula -NHS(O)2Rb, -S(O)2NHR c , NHC(X 2 )NHRb, or a tetrazolyl; wherein X2 is oxygen or sulfur, preferably oxygen.
  • the functional group is other than a sulfonic acid, either directly or as a substituent group on the aryl, heteroaryl, or heterocyclic moiety ring, such as in SR2 or OR2- More preferably R is OH, SH, or NHS(O)2Rb-
  • R2 is a substituted aryl, heteroaryl, or heterocyclic moiety which ring has the functional moiety providing the ionizable hydrogen having a pKa of 10 or less.
  • R6' and R7* are hydrogen, C j-4 alkyl, aryl, arylC i -4alkyl, arylC2-4alkenyl, heteroaryl, heteroarylC i -4alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclic Ci-4alkyl, heterocyclic C2-4alkenyl moiety , all of which may be optionally substituted one to three times independently by halogen; nitro; halosubstituted C i-4 alkyl, such as CF3; C) _4 alkyl, such as methyl; C i -4 alkoxy, such as methoxy; NR9C(O)R a ; C(O)NR ⁇ R7; S(O)3H; or C(O)OC i-4 alkyl, provided that only one of R6' and R7' are hydrogen, but not both.
  • R6 and R7 are independently hydrogen or a C i-4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur. This heteroring may be optionally substituted as defined herein.
  • R a is an alkyl, aryl, arylC ⁇ _4alkyl, heteroaryl, heteroarylC 1 _4alkyl, heterocyclic, or a heterocyclic C ⁇ _4alkyl moiety, all of which may be optionally substituted, as defined herein below.
  • R is a NR6R7 , alkyl, aryl, arylCi-4alkyl, arylC2-4alkenyl, heteroaryl, heteroarylC i-4alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclic C i-4alkyl, heterocyclic C2-4alkenyl moiety, or camphor, all of which may be optionally substituted one to three times independently by halogen; nitro; halosubstituted C -4 alkyl, such as CF3; Cj-4 alkyl, such as methyl; C1-4 alkoxy, such as ethoxy; NR9C(O)R a ; C(O)NR6R7; S(O)3H; or C(O)OCi-4 alkyl.
  • Rb is preferably an optionally substituted phenyl, benzyl, or styryl.
  • Rb is a heteroaryl preferably it is an optionally substituted thiazole, optionally substituted thienyl, or optionally substituted quinolinyl ring.
  • R9 is hydrogen or a Ci-4 alkyl, preferably hydrogen.
  • R a is preferably an alkyl group, such as methyl.
  • R c is hydrogen, alkyl, aryl, arylC 1 -4alkyl, arylC 1 _4alkenyl, heteroaryl, heteroarylC i-4alkyl, heteroarylC i-4alkenyl, heterocyclic, or heterocyclic C i-4alkyl, or a heterocyclic C ⁇ _4alkenyl moiety, all of which may be optionally substituted one to three times independently by halogen, nitro, halosubstituted Ci-4 alkyl, C 1-4 alkyl, Cj-4 alkoxy, NR9C(O)R a , C(O)NR6R7, S(O)3H, or C(O)OC ⁇ _4 alkyl, wherein R9 is hydrogen or a Cj-4 alkyl.
  • Rc is an optionally substituted phenyl.
  • R is an OR2 or SR2 moiety it is recognized by one of skill in the art that the aryl ring must, therefore, contain the required ionizable hydrogen.
  • the aryl ring may also be additionally substituted, independently, by one to three groups, which groups may also contain an additional ionizable group, and which include but are not limited to, halogen, nitro, halosubstituted Ci-4 alkyl, C -4 alkyl, C ⁇ -4 alkoxy, hydroxy, SH, -C(O)NR6'R7', -NH-C(O)R a , -NHS(O)2Rb, S(O)2NR6R7, C(O)OR 8 , or a tetrazolyl ring.
  • Rl is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted Ci-io alkyl, such as CF3; C]-io alkyl, such as methyl, ethyl, isopropyl, or n-propyl; C2-10 alkenyl; Cj-io alkoxy, such as methoxy, or ethoxy; halosubstituted Ci-io alkoxy, such as trifluoromethoxy; azide; (CR R )q S(O) t R4, wherein t is 0, 1 or 2; hydroxy; hydroxy Ci-4alkyl, such as methanol or ethanol; aryl, such as phenyl or naphthyl; aryl Ci-4 alkyl, such as benzyl; aryloxy, such as phenoxy; aryl C1-4 alkyloxy, such as benzyloxy; heteroaryl; heteroarylal
  • NHS(O)2Rj9, (CR 8 R 8 )qS(O)2NR4R5; or two Rj moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring; and s is an integer having a value of 1 to 3.
  • the aryl , heteroaryl, and heterocyclic containing moieites may be optionally substituted as defined herein below.
  • q is 0, or an integer having a value of 1 to 10.
  • R 1 When R 1 forms a dioxybridge, s is preferably 1. When R 1 forms an additional saturated or unsaturated 5 to 6 membered ring, it is preferably 6 membered ring with unsaturation, resulting in a naphthylene ring system. This naphthylene ring may be substituted independently, 1 to 3 times by the other R 1 moieties as defined above.
  • R4 and R5 are independently hydrogen, optionally substituted C ⁇ .4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Cj-4alkyl, heterocyclic, heterocyclicC 1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S.
  • R 8 is suitably independently selected from hydrogen or C]-4 alkyl.
  • RlO is suitably C 1-10 alkyl C(O)2R8> such as CH2C(O)2H or CH 2 C(O)2CH3.
  • Rl 1 is suitably hydrogen, Ci-4 alkyl, aryl, aryl C)-4 alkyl, heteroaryl, heteroaryl Ci-4alkyl, heterocyclic, or heterocyclic C i-4alkyl.
  • Rl2 is suitably hydrogen, Cl-10 alkyl, optionally substituted aryl or optionally substituted arylalkyl.
  • Rl9 is Ci-4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC i-4alkyl, heterocyclic, or heterocyclicC i-4alkyl, wherein the all of these moieties may be optionally substituted;
  • Rj is halogen, cyano, nitro, CF3, C(O)NR4R5, alkenyl
  • R4 and R5 are both hydrogen or one is phenyl.
  • a preferred ring substitution for Rj is in the 4-position of the phenyl ring.
  • R is OH, SH or NSO2Rb than Ri is preferably substituted in the 3- position, the 4- position or di substituted in the 3,4- position.
  • the substituent group is suitably an electron withdrawing moiety.
  • R is OH, SH or NSO2Rb * than Ri is nitro, halogen, cyano, trifluoromethyl group, C(O)NR4R5.
  • R ⁇ is carboxylic acid
  • R ⁇ is preferably hydrogen, or R] is preferably substituted in the 4-position, more preferably substituted by trifluoromethyl or chloro.
  • R13 and R 14 are independently hydrogen, optionally substituted C 1 -4 alkyl which may be straight or branched as defined herein, or one of R13 and R14 are an optionally substituted aryl; v is 0, or an integer having a value of 1 to 4.
  • Rj 3 or R 14 are an optionally substituted alkyl
  • the alkyl moiety may be substituted one to three times independently by halogen; halosubstituted Cj-4 alkyl such as trifluromethyl; hydroxy; hydroxy Ci-4alkyl, C1-4 alkoxy; such as methoxy, or ethoxy, halosubstituted C ⁇ _ 10 alkoxy, S(O)tR4; aryl; NR4R5; NHC(O)R4; C(O)NR4R5; or C(O)OR 8 .
  • Wj is suitably any organic compound of Formula (I).
  • the E containing ring denoted by its point of attachment through the asterix (*) may optionally be present. If if it is not present the ring is a phenyl moiety which is substituted by the Y terms as shown herein.
  • the E ring may be substituted by the Y moiety in any ring, saturated or unsaturated, and is shown for purposes herein substituted only in the unsaturated ring(s).
  • Y is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted C i-io alkyl; C i-io alkyl; C2-10 alkenyl; C j-io alkoxy; halosubstituted Ci-io alkoxy; azide; (CR 8 R 8 )q S(O)tR4; hydroxy; hydroxyCi-4alkyl; aryl; aryl Ci-4 alkyl; aryloxy; arylCi-4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl Cj-4 alkyloxy; heterocyclic, heterocyclic Ci-4alkyl; aryl C2-10 alkenyl; heteroaryl C2-10 alkenyl; heterocyclic C2-10 alkenyl; (CR R )q NR4R5; C2-IO alkenyl C(O)NR4R5; (CR 8 R 8 )q C(O)NR 4
  • s is preferably 1.
  • Y forms an additional saturated or unsaturated ring, it is preferably 6 membered ring resulting in a naphthylene ring system.
  • This naphthylene ring may be substituted 1 to 3 times by other Y moieties as defined above.
  • the aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heterocyclic, heterocyclicalkyl, and heterocyclicalkenyl moieties noted above may all be optionally substituted as defined herein.
  • Rj is a NR ⁇ R7, alkyl, aryl Cj_4 alklyl, arylC 2-4 alkenyl, heteroaryl, hetroaryl-C ⁇ _4alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclicC] .4 alkyl, or heterocyclic C 2-4 alkenyl moiety, wherein the aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heterocyclic, and heterocyclicalkyl, and heterocyclicalkenyl moieties noted above may all be optionally substituted as defined herein.
  • Y is preferably a halogen, Ci-4 alkoxy, optionally substituted aryl, optionally substituted aryloxy or arylalkoxy, methylene dioxy, NR4R5, thio C i-4alkyl, thioaryl, halosubstituted alkoxy, optionally substituted C ] -4 alkyl, or hydroxy alkyl.
  • Y is more preferably mono-substituted halogen, disubstituted halogen, mono-substituted alkoxy, disubstituted alkoxy, methylenedioxy, aryl, or alkyl, more preferably these groups are mono or di-substituted in the 2'- position or 2'-, 3'-position.
  • Y may be substituted in any of the 5 ring positions
  • Y is preferably mono-substituted in the 2'-position or 3'- position, with the 4'- preferably being unsubstituted; more preferably R is OH, SH, or NSO2Rb- If the ring is disubstituted, preferably when R is OH, SH, or NSO2Rb. th en the substituents are preferably in the 2' or 3' position of a monocyclic ring. While both Ri and Y can both be hydrogen, it is prefered that at least one of the rings be substituted, preferably both rings are substituted.
  • Z is suitably cyano, OR] ⁇ , C(0)NRi5Rjg, R 18 , C(O)Rn , or S(O) 2 Ri7-
  • R15 and Rjg are independently hydrogen, optionally substituted
  • C i-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC ] -4alkyl, optionally substituted heterocyclic, optionally substituted heterocyclicC ]-4alkyl, or Rj5 and R jg may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur.
  • R17 is Ci-4 alkyl, NR15R16, OR ] j, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC j-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC] _4alkyl.
  • Rjg is optionally substituted Cj-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC ⁇ _4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC ⁇ _4alkyl.
  • the A containing ring, depicted below represents a substituted pyridyl or pyrimidine ring.
  • a moieites may be nitrogen, this would yield a 3, 4, 5, or 6- pyridyl ring, or a 2,4- or 3,5-pyrimidine ring.
  • the ring may be substituted by R j as noted above, yielding such rings as 2,4-dihydroxy-3,5- pyrimidyl; 2-hydroxy-4-sufanilamide-3,5-pyrimidyl; 2-hydroxy-4-sulfhydryl-6- amino-3,5-pyrimidyl; 3-hydroxypyridin-2-yl; 2-hydroxyl-3-pyridyl; 2,4,-dihydroxy- 6-methyl-5-pyridyl; 2-hydroxy-5-pyridyl or 2-sulfhydryl-5-pyridyl.
  • halogen such as fluorine, chlorine, bromine or iodine
  • hydroxy such as fluorine, chlorine, bromine or iodine
  • C i-io alkoxy such as methoxy or ethoxy
  • S(O)m' Ci-io alkyl wherein m' is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl
  • amino, mono & di-substituted amino such as in the NR4R5 group; NHC(O)R4; C(O)NR4Rs; C(O)OH; S(O)2NR4R5; NHS(O)2R21 , -10 alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl
  • halosubstituted Ci-io alkyl such CF3
  • an optionally substituted such as fluorine, chlorine, bromine or
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
  • pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety.
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.
  • halo all halogens, that is chloro, fluoro, bromo and iodo.
  • C j - ioalkyl or "alkyl” - both straight and branched chain radicals of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, «-propyl, w ⁇ -propyl, n-butyl, sec-butyl, iso-butyl, tert- butyl, n-pentyl and the like.
  • cycloalkyl is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • alkenyl is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl- l- propenyl, 1 -butenyl, 2-butenyl and the like. • "aryl” - phenyl and naphthyl;
  • heteroaryl (on its own or in any combination, such as “heteroaryloxy”, or “heteroaryl alkyl”) - a 5- 10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.
  • heterocyclic (on its own or in any combination, such as “heterocyclicalkyl”) - a saturated or partially unsaturated 4- 10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, or imidazolidine.
  • arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean Cj- io alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.
  • sulfinyl - the oxide S (O) of the corresponding sulfide
  • thio refers to the sulfide
  • sulfonyl refers to the fully oxidized S(O)2 moiety.
  • R i moieties may together form a 5 or 6 membered saturated or unsaturated ring
  • a napthylene ring system or a phenyl moiety having attached a 6 membered partially unsaturated ring such as a C ⁇ cycloalkenyl, i.e hexene, or a C5 cyloalkenyl moiety, cyclopentene.
  • the compounds of the present invention may exist as stereoisomers, regioisomers, or diastereiomers. These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are included within the scope of the present invention.
  • the compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below. The synthesis provided for in these Schemes is applicable for the producing compounds of Formula (I) having a variety of different R, R ⁇ , and Aryl groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. Once the urea nucleus has been established, further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art. While the schemes are shown with compounds only of Formula (I) this is merely for illustration purposes only.
  • the thiouronium salt(2 ⁇ Scheme 1) can be synthesized by reacting sodium cyanamide with a commercially available isothiocyanate 1 (if the isothiocyanate is not commercially available it can be synthesized by reacting the desired amine with thiophosgene in the presence of a base like sodium bicarbonate).
  • the thiouronium salt (2) can then be condensed with the appropriate substituted aniline in the presence of a coupling reagent like EDC-HCl or acidified to form the cyanothiourea and then reacted.
  • Alternatively 4 can be synthesized by reacting the commercially available (Aldrich Chem. Co.), diphenyl cyanocarboimidate (5, Scheme 2) with an amine to form an intermediate O-phenylisourea 6_which then reacts with the appropriately substituted aniline in the presence of trimethyl aluminum by the method of Atwal. (Atwal, K. S., Tetrahedron Lett, 35, 8085 (1994).).
  • Compounds wherein R' is alkyl may be prepared by heating with the appropriately substituted alkyla ine, but without the presence of catalyst.
  • the title compound can be synthesized using a protected ortho- substituted aniline (8, Scheme 3, See synthesis as described in US provisional application USSN 60/020655 filed June 27, 1996, Attorney Docket No.: P50467P; WO96/25157 filed 22 August 1996, Widdowson et al. (Attorney Docket No.: P50324-1); and USSN 08/701,299 filed 21 August 1996 (Attorney Docket No.: P50324-2) whose disclosures are incorporated herein by reference in their entireties.
  • An ortho-substituted aniline (7, Scheme 3) is first protected (ie.
  • tert-butyl dimethyl silyl, allyl, benzyl, mom or other suitable protecting group by reacting the ortho- substituted aniline with the appropriate alkyl or silyl halide in the presence of a suitable base (ie. cesium carbonate, potassium carbonate or imidazole) in an aprotic solvent.
  • a suitable base ie. cesium carbonate, potassium carbonate or imidazole
  • the protected ortho-substituted aniline may also be synthesized from an ortho-substituted nitrobenzene (9 ) by reacting it with a protecting group under conditions well known in the art (see Greene, T Protecting Groups in Organic
  • This protected ortho-substituted aniline (8) can then be converted into an isothiocyanate using thiophosgene and then reacted with the anion ZNH" (formed from reaction of ZNH2 with a base such as NaH).
  • Z is as defined in compounds of
  • the thioimidate (JO, Scheme 5) can be converted to the title compound 4 by reaction with the amine R'NH2- This reaction can be accelerated by the addition of metal salt with a high affinity for sulfur such as mercuric oxide or silver acetate or by oxidation of the sulfur with dimethyloxirane to form a better leaving group. Finally the phenol protection is removed by standard methods to form the title compound 4.
  • a protected carbodiimide JJ., Scheme 6
  • the anion NH-Z formed from reaction of NH2Z with a base such as NaH
  • a neutral species NH Z (Z CN)
  • a tertiary amine base such as Hunig's base or triethylamine
  • the carbodiimide ⁇ is prepared from the thiourea (12a. Scheme 7) by treatment with phosgene and a tertiary amine or from the thiourea (12a) or urea (12b) by reaction with triphenylphosphine, carbon tetrachloride and triethylamine.
  • the carbodiimide may also be prepared by reaction of the thiourea (12b) with methanesulfonyl chloride and a tertiary amine base like tnethyl amine as described b by Fell and Coppola (Fell ,J. B., Coppola, J B , Syn Communications 25, 43, ( 1995)
  • the thiourea or urea is synthesized as described in the US provisional application USSN 60/020655 filed June 27, 1996, Attorney Docket No. P50467P and Attorney Docket No.: P50324-2P, supra.
  • the thiourea (J a, Scheme 8) may also be prepared by reaction of the protected ortho-substituted aniline and two equivalents of an appropriate base such as NaH or KH and reacting this anion with a commercially available isothiocyanate. If the desired isothiocyanate is not commercially available, it may be prepared by reaction of a corresponding aniline with thiophosgene and a suitable base such as sodium bicarbonate.
  • the compounds of Formula (I), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and or macrophages, or other chemokines which bind to the IL-8 ⁇ or ⁇ receptor, also referred to as the type I or type II receptor.
  • the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 ⁇ or ⁇ receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the chemokines are IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2.
  • the compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 , such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state.
  • Abnormal levels of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 for instance in the context of the present invention constitute: (i) levels of free IL-8 greater than or equal to 1 picogram per mL; (ii) any cell associated IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 above normal physiological levels; or (iii) the presence of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 above basal levels in cells or tissues in which IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 respectively, is produced.
  • Chemokine mediated diseases include psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction, alzheimers disease, allograft rejections, malaria, restinosis, angiogenesis or undesired hematopoietic stem cells release.
  • IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ or NAP-2 has the unique property of promoting neutrophil chemotaxis, enzyme release including but not limited to clastase release as well as superoxide production and activation.
  • the ⁇ -chemokines but particularly, GRO ⁇ , GRO ⁇ , GRO ⁇ or NAP-2, working through the IL-8 type I or II receptor can promote the neovascularization of tumors by promoting the directional growth of endothelial cells. Therefore, the inhibition of IL-8 induced chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration.
  • the present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I).
  • CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region. Also included within this definition is ischemic stroke, particularly to the brain area.
  • Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel.
  • the role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.
  • TNF- ⁇ is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression. Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu et al., Stoke, Vol. 25., No.
  • the compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8, binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation.
  • the discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the in vitro receptor binding assays which are described herein.
  • the compounds of Formula (I) have been shown to be inhibitors of type II IL-8 receptors.
  • IL-8 mediated disease or disease state refers to any and all disease states in which IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 plays a role, either by production of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 themselves, or by IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, or NAP-2 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF.
  • a disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.
  • chemokine mediated disease or disease state refers to any and all disease states in which a chemokine which binds to an IL-8 ⁇ or ⁇ receptor plays a role, such as but not limited to IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA- 78, or NAP-2.
  • a disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.
  • cytokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response.
  • a cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them.
  • a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte.
  • Lymphokines are generally referred to as being produced by lymphocyte cells.
  • cytokines include, but are not limited to, Interleukin- 1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- ⁇ ) and Tumor Necrosis Factor beta (TNF- ⁇ ).
  • chemokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term “cytokine” above.
  • a chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells.
  • chemokines include, but are not limited to, IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78, NAP-2, IP-10, MlP-l ⁇ , MlP- ⁇ , PF4, and MCP 1, 2, and 3.
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
  • This invention also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.
  • Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation.
  • the compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures.
  • the compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg.
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • Compounds of Formula (I) may be administered topically, that is by non- systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1 % to 2% by weight of the Formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the Formulation.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base.
  • the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel.
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 C. for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01 %).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
  • Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
  • the daily oral dosage regimen will preferably be from about 0.01 to about 80 mg kg of total body weight.
  • the daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight.
  • the daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.
  • the daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day.
  • the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • IL-8, and Gro- ⁇ chemokine inhibitiory effects of compounds of the present invention are determined by the following in vitro assay: Receptor Binding Assays: [ ⁇ I] IL-8 (human recombinant) is obtained from Amersham Corp.,
  • homogenization buffer is changed to lOmM Tris-HCL, ImM MgS04, 0.5mM EDTA (ethylene-diaminetetra- acetic acid), ImMPMSF ( ⁇ -toluenesulphonyl fluoride), 0.5 mg/L Leupeptin, pH 7.5.
  • Membrane protein concentration is determined using Pierce Co. micro-assay kit using bovine serum albumin as a standard. All assays are performed in a 96-well micro plate format.
  • Each reaction mixture contains 125j JL_ (0.25 nM) or 25] Gro- ⁇ and 0.5 ⁇ g/mL of IL-8R ⁇ or 1.0 ⁇ g/mL of IL-8R ⁇ membranes in 20 mM Bis- Trispropane and 0.4 mM Tris HC1 buffers, pH 8.0, containing 1.2 mM MgS ⁇ 4, 0.1 mM EDTA, 25 mM NaCl and 0.03% CHAPS.
  • drug or compound of interest ss added which has been pre-dissolved in DMSO so as to reach a final concentration of between O.OlnM and 100 uM.
  • the assay is initiated by addition of I2 ⁇ I-IL-8. After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethylenimine/0.5% BSA and washed 3 times with 25 mM NaCl, 10 mM
  • the filter is then dried and counted on the Betaplate liquid scintillation counter.
  • the recombinant IL- 8 R ⁇ , or Type I, receptor is also referred to herein as the non-permissive receptor and the recombinant IL-8 R ⁇ , or Type II, receptor is referred to as the permissive receptor.
  • GRO- ⁇ , GRO- ⁇ and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0.1 and 100 nM.
  • the two chambers are separated by a 5um polycarbonate filter.
  • compounds of this invention are tested, they are mixed with the cells (0.001 - 1000 nM) just prior to the addition of the cells to the upper chamber. Incubation is allowed to proceed for between about 45 and 90 min at about 37°C in a humidified incubator with 5% CO2- At the end of the incubation period, the polycarbonate membrane is removed and the top side washed, the membrane then stained using the Diff Quick staining protocol (Baxter Products, McGaw Park, IL, USA).
  • Cells which have chemotaxed to the chemokine are visually counted using a microscope. Generally, four fields are counted for each sample, these numbers are averaged to give the average number of cells which had migrated. Each sample is tested in triplicate and each compound repeated at least four times. To certain cells (positive control cells) no compound is added, these cells represent the maximum chemotactic response of the cells. In the case where a negative control (unstimulated) is desired, no chemokine is added to the bottom chamber. The difference between the positive control and the negative control represents the chemotactic activity of the cells.
  • the compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils.
  • Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7.23.1.
  • PMNs 0.88 x 10 6 cells suspended in Ringer's Solution (NaCl 1 18, KC1 4.56, NaHCO3 25, KH2PO4 1.03, Glucose 1 1.1, HEPES 5 mM, pH 7.4) are placed in each well of a 96 well plate in a volume of 50 ul.
  • test compound 0.001 - 1000 nM
  • Cytochalasin B in a volume of 50 ul (20ug/ml)
  • Ringers buffer in a volume of 50 ul.
  • These cells are allowed to warm (37 °C, 5% CO2, 95% RH) for 5 min before IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ or NAP-2 at a final concentration of 0.01 - 1000 nM was added.
  • the reaction is allowed to proceed for 45 min before the 96 well plate is centrifuged (800 xg 5 min) and 100 ul of the supernatant removed.
  • This suppernatant is added to a second 96 well plate followed by an artificial elastase substrate (MeOSuc-Ala- Ala-Pro- Val- AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml dissolved in phosphate buffered saline.
  • the plate is placed in a fluorescent 96 well plate reader (Cytofluor 2350, Millipore, Bedford, MA) and data collected at 3 min intervals according to the method of Nakajima et al J. Biol Chem 254 4027 ( 1979).
  • the amount of Elastase released from the PMNs is calculated by measuring the rate of MeOSuc-Ala-Ala-Pro-Val-AMC degradation.
  • TNF- ⁇ in Traumatic Brain Injury Assay provides for examination of the expression of tumor necrosis factor mRNA in specfic brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats.
  • TBI experimentally induced lateral fluid- percussion traumatic brain injury
  • LC left (injured) parietal cortex
  • RC contralateral right cortex
  • LA cortex adjacent to injured parietal cortex
  • RA right cortex
  • RH right hippocampus
  • TNF- ⁇ mRNA expression is observed in LH ( 104 ⁇ 17% of positive control, p ⁇ 0.05 compared with sham), LC ( 105 ⁇ 21%, p ⁇ 0.05) and LA (69 ⁇ 8%, p ⁇ 0.01) in the traumatized hemisphere 1 hr. following injury.
  • An increased TNF- ⁇ mRNA expression is also observed in LH (46 ⁇ 8%, p ⁇ 0.05), LC (30 ⁇ 3%, p ⁇ 0.01 ) and LA (32 ⁇ 3%, p ⁇ 0.01) at 6 hr. which resolves by 24 hr. following injury.
  • TNF- ⁇ mRNA In the contralateral hemisphere, expression of TNF- ⁇ mRNA is increased in RH (46 ⁇ 2%, p ⁇ 0.01 ), RC (4 ⁇ 3%) and RA (22 ⁇ 8%) at 1 hr. and in RH (28 ⁇ 1 1 %), RC (7 ⁇ 5%) and RA (26 ⁇ 6%, p ⁇ 0.05) at 6 hr. but not at 24 hr. following injury. In sham (surgery without injury) or naive animals, no consistent changes in expression of TNF- ⁇ mRNA are observed in any of the 6 brain areas in either hemisphere at any times.
  • TNF- ⁇ is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- ⁇ plays an important role in both the acute and regenerative response to CNS trauma.
  • NGF nerve growth factor
  • CNS Iniurv model for IL- ⁇ mRNA This assay characterizes the regional expression of interleukin- 1 ⁇ (IL- 16) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats.
  • TBI lateral fluid-percussion traumatic brain injury
  • LC left (injured) parietal cortex
  • RC contralateral right cortex
  • LA cortex adjacent to injured parietal cortex
  • RA right cortex
  • LH left hippocampus
  • RH right hippocampus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de la formule (I) et des compositions desdits composés servant dans le traitement d'états maladifs véhiculés par l'agent chimique Interleukine-8 (IL-8).
PCT/US1997/014582 1996-08-15 1997-08-15 Antagonistes du recepteur il-8 WO1998006398A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP10510107A JP2000516620A (ja) 1996-08-15 1997-08-15 Ｉｌ―８レセプターアンタゴニスト
EP97938426A EP0939634A4 (fr) 1996-08-15 1997-08-15 Antagonistes du recepteur il-8

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2397296P 1996-08-15 1996-08-15
US60/023,972 1996-08-15

Publications (1)

Publication Number Publication Date
WO1998006398A1 true WO1998006398A1 (fr) 1998-02-19

Family

ID=21818184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014582 WO1998006398A1 (fr) 1996-08-15 1997-08-15 Antagonistes du recepteur il-8

Country Status (3)

Country Link
EP (1) EP0939634A4 (fr)
JP (1) JP2000516620A (fr)
WO (1) WO1998006398A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044967A2 (fr) * 1999-04-13 2000-10-18 Pfizer Inc. 2-Pyridinylguanidines utilisées en tant qu'inhibiteurs d'urokinase
US6218539B1 (en) 1996-06-27 2001-04-17 Smithkline Beecham Corporation IL-8 receptor antagonists
EP1180028A1 (fr) * 1999-05-28 2002-02-20 Smithkline Beecham Corporation Antagonistes du recepteur d'il-8
WO2001072830A3 (fr) * 2000-03-31 2002-06-20 Ipf Pharmaceuticals Gmbh Medicament et moyen diagnostique pour analyser le proteome de surface de cellules tumorales et inflammatoires, et pour traiter des maladies tumorales et inflammatoires, de preference au moyen d'une analyse specifique des recepteurs de chimiokines et de l'interaction de ligands recepteurs de chimiokines
WO2004074260A1 (fr) * 2003-02-21 2004-09-02 Kyowa Hakko Kogyo Co., Ltd. Dérivés de pyrimidine
US7326729B2 (en) 2004-05-12 2008-02-05 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
US7709485B2 (en) 2002-10-29 2010-05-04 Glaxosmithkline Llc IL-8 receptor antagonists
US7893089B2 (en) 2006-04-21 2011-02-22 GlaxoSmithKline, LLC IL-8 receptor antagonists
US8097626B2 (en) 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262415A (en) * 1991-03-15 1993-11-16 The Green Cross Corporation Aminopyridine compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908063D0 (en) * 1989-04-11 1989-05-24 Beecham Group Plc Novel compounds
WO1994004499A1 (fr) * 1992-08-13 1994-03-03 The Upjohn Company Des cyanoguanidines, agents bloquants du canal potassium
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5312831A (en) * 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262415A (en) * 1991-03-15 1993-11-16 The Green Cross Corporation Aminopyridine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0939634A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218539B1 (en) 1996-06-27 2001-04-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6583162B1 (en) 1999-04-13 2003-06-24 Warner-Lambert Company 2-pyridinylguanidine urokinase inhibitors
EP1044967A3 (fr) * 1999-04-13 2001-02-07 Pfizer Inc. 2-Pyridinylguanidines utilisées en tant qu'inhibiteurs d'urokinase
EP1044967A2 (fr) * 1999-04-13 2000-10-18 Pfizer Inc. 2-Pyridinylguanidines utilisées en tant qu'inhibiteurs d'urokinase
US6673789B2 (en) 1999-04-13 2004-01-06 Pfizer, Inc. 2-pyridinylguanidine urokinase inhibitors
EP1180028A1 (fr) * 1999-05-28 2002-02-20 Smithkline Beecham Corporation Antagonistes du recepteur d'il-8
JP2003500447A (ja) * 1999-05-28 2003-01-07 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US6566387B1 (en) 1999-05-28 2003-05-20 Smithkline Beecham Corporation IL-8 receptor antagonists
EP1180028A4 (fr) * 1999-05-28 2002-10-23 Smithkline Beecham Corp Antagonistes du recepteur d'il-8
WO2001072830A3 (fr) * 2000-03-31 2002-06-20 Ipf Pharmaceuticals Gmbh Medicament et moyen diagnostique pour analyser le proteome de surface de cellules tumorales et inflammatoires, et pour traiter des maladies tumorales et inflammatoires, de preference au moyen d'une analyse specifique des recepteurs de chimiokines et de l'interaction de ligands recepteurs de chimiokines
US7709485B2 (en) 2002-10-29 2010-05-04 Glaxosmithkline Llc IL-8 receptor antagonists
WO2004074260A1 (fr) * 2003-02-21 2004-09-02 Kyowa Hakko Kogyo Co., Ltd. Dérivés de pyrimidine
US7326729B2 (en) 2004-05-12 2008-02-05 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
US7893089B2 (en) 2006-04-21 2011-02-22 GlaxoSmithKline, LLC IL-8 receptor antagonists
US8097626B2 (en) 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists

Also Published As

Publication number Publication date
EP0939634A1 (fr) 1999-09-08
JP2000516620A (ja) 2000-12-12
EP0939634A4 (fr) 2001-02-21

Similar Documents

Publication Publication Date Title
US6218539B1 (en) IL-8 receptor antagonists
US6133319A (en) IL-8 receptor antagonists
AU723816B2 (en) IL-8 receptor antagonists
WO1997049399A1 (fr) Antagonistes des recepteurs d'il-8
US6214881B1 (en) IL-8 receptor antagonists
EP0920417A1 (fr) Antagonistes du recepteur de l'il-8
US6335352B1 (en) IL-8 receptor antagonists
EP0939634A1 (fr) Antagonistes du recepteur il-8
US6248785B1 (en) IL-8 receptor antagonists
US6177448B1 (en) IL-8 receptor antagonists
WO2000072800A2 (fr) Antagonistes du recepteur d'il-8
WO1998006262A1 (fr) Antagonistes du recepteur il-8
EP0915653A1 (fr) Antagonistes des recepteurs d'il-8
EP0948330A1 (fr) Antagonistes du recepteur d'il-8
WO2000076457A2 (fr) Antagonistes du recepteur il-8
EP1185270A1 (fr) Antagonistes des recepteurs de il-8
AU766086B2 (en) IL-8 receptor antagonists
WO2000076508A1 (fr) Recepteurs antagonistes il-8
WO2000073282A1 (fr) Antagonistes du recepteur d'il-8
WO2000069435A1 (fr) Antagonistes de recepteur il-8

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09230952

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 510107

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997938426

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997938426

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997938426

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载